Study identifier:D419MR00003
ClinicalTrials.gov identifier:NCT06494540
EudraCT identifier:N/A
CTIS identifier:N/A
Prospective non-interventional study (NIS) to examine the effectiveness of Tremelimumab + Durvalumab + platinum chemotherapy (TDC) in patients with metastatic non-squamous NSCLC and high-risk genetic alterations
non-squamous metastatic non-Small-Cell Lung Carcinoma
N/A
No
-
All
600
Observational
18 Years - 120 Years
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Oct 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
- |